Genetic dissection of eosinophilic esophagitis provides insight into disease pathogenesis and treatment strategies

Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio 45229, USA.
The Journal of allergy and clinical immunology (Impact Factor: 11.25). 05/2011; 128(1):23-32; quiz 33-4. DOI: 10.1016/j.jaci.2011.03.046
Source: PubMed

ABSTRACT Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder of the esophagus that is compounded by both genetic predisposition and aberrant responses to environmental antigens, particularly those that are food derived. Data have indicated a unique transcriptional response in vivo that defines EoE and that appears to be partially attributable to the T(H)2 cytokine IL-13. Moreover, a number of genetic risk variants in proinflammatory and epithelial cell genes associate with EoE susceptibility, demonstrating novel heritable mechanisms that contribute to disease risk. Here we discuss recent advances in our understanding of the intrinsic (genetic) and extrinsic (environmental) components that illustrate the complex nature of EoE.

  • [Show abstract] [Hide abstract]
    ABSTRACT: La pathologie gastro-intestinale à éosinophiles peut toucher le tube digestif à tous ses niveaux, de l’oesophage au côlon. Parmi ses diverses formes allant de l’oesophagite à la gastrite, en passant par la gastro-entérite, vers la colite, l’oesophagite à éosinophiles se rencontre le plus fréquemment. Elle est souvent liée à un terrain d’atopie. Sa fréquence est peu importante, mais de plus en plus reconnue. L’interleukine 5 joue un rôle clé dans le recrutement des éosinophiles au niveau digestif. De ce fait, l’anticorps monoclonal anti-IL-5 a été récemment évalué dans le traitement de ces atteintes. Le but de notre travail est de décrire à travers quatre observations les caractéristiques cliniques, paracliniques, thérapeutiques et évolutives de cette atteinte.
    Journal Africain d?Hépato-Gastroentérologie 06/2013; 7(2). DOI:10.1007/s12157-013-0447-2
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Previous studies indicated that a P2X receptor other than the P2X1 subtype might be present in rat large, but not small pulmonary arteries. The aim here was to characterise further these P2X receptors. Isometric tension was recorded from rat isolated small (i.d. 250-500 μm) and large pulmonary artery (i.d. 1-1.5 mm) rings mounted on a wire myograph. In both tissues the P2X receptor agonist α,β-meATP evoked rapidly-developing contractions that were inhibited by the P2X antagonists NF449, PPADS and suramin in a concentration-dependent manner and eventually abolished by each. The rank order of the potency in both tissues was NF449>PPADS=suramin. For each antagonist there was no significant difference between its potency in the small and large pulmonary arteries. Prolonged administration of a high concentration of α,β-meATP induced complete desensitisation in both tissues. RT-PCR followed by PCR with specific oligonucleotide primers, identified mRNA for all seven P2X subunits. Subtype-specific antibodies showed strong, punctate P2X1 receptor-like immunoreactivity in the majority of cells and faint, punctate staining with the anti-P2X2 and anti-P2X4 antibodies, whilst P2X5-like immunoreactivity was barely detectable and no P2X3, P2X6, and P2X7 receptor-like immunoreactivity was seen. No differences in P2X mRNA and protein expression were seen between small and large pulmonary arteries. In conclusion, the pharmacological properties and mRNA and protein expression profiles of P2X receptors in rat small and large pulmonary arteries are very similar. Thus P2X1 appears to be the predominant P2X subunit functionally expressed in smooth muscle cells of rat small and large pulmonary arteries.
    European journal of pharmacology 12/2010; 649(1-3):342-8. DOI:10.1016/j.ejphar.2010.09.041 · 2.68 Impact Factor
  • Source
    Gastroenterology 01/2011; 140(5). DOI:10.1016/S0016-5085(11)60554-4 · 13.93 Impact Factor
Show more


Available from